Cytotoxicity of MGL-BL929 in human cells
| Cancer Cell Line | Tumor Type | IC50 of MGL-BL929 in U/ml (95% CI) |
|---|---|---|
| HCT116 | Colorectal carcinoma | 0.18 (0.13–0.25) |
| HT29 | Colorectal carcinoma | 0.56 (0.49–0.64) |
| LoVo | Colorectal carcinoma | 1.32 (1.22–1.42) |
| SW480a | Colorectal carcinoma | >3.5 |
| SW620a | Colorectal carcinoma | >3.5 |
| HeLa | Cervix adenocarcinoma | 0.76 (0.46–1.26) |
| A431 | Vulvar epidermoid carcinoma | 0.84 (0.58–1.20) |
| HUH7 | Hepatocellular carcinoma | 1.84 (1.77–1.93) |
| MAHLAVU | Hepatocellular carcinoma | 1.78 (1.67–1.89) |
| HepG2 | Hepatoblastoma | 0.78 (0.61–0.99) |
| HOON | Pre-B-cell acute lymphocytic leukemia | 0.29 (0.19–0.46) |
| REH | Pre-B cell acute lymphocytic leukemia | 0.05 (0.02–0.14) |
| JURKAT | T-Cell acute lymphocytic leukemia | 0.16 (0.07–0.37) |
| K562 | CML blast crisis | 0.20 (0.13–0.30) |
| HEL | Erythroleukemia | 0.15 (0.08–0.27) |
| HL-60 | Acute promyelocytic leukemia | 0.08 (0.04–0.16) |
| KG-1 | Acute myelocytic leukemia | 0.48 (0.29–0.79) |
| BJAB | Burkitt’s lymphoma | 0.35 (0.31–0.40) |
| RAJI | Burkitt’s lymphoma | 0.18 (0.12–0.28) |
| U-2 OS | Osteosarcoma | 0.59 (0.45–0.76) |
| HT-1080 | Fibrosarcoma | 0.64 (0.57–0.72) |
| PC-3 | Prostate adenocarcinoma | 0.80 (0.77–0.84) |
| OVCAR3 | Ovarian adenocarcinoma | 0.74 (0.53–1.05) |
| SKOV3 | Ovarian adenocarcinoma | 1.26 (1.06–1.51) |
| AsPC1 | Pancreas adenocarcinoma | 0.17 (0.09–0.35) |
| MCF7 | Mammary adenocarcinoma | 0.58 (0.23–1.43) |
| MDA-MB231 | Mammary adenocarcinoma | 0.61 (0.58–0.65) |
| SKBR3 | Mammary adenocarcinoma | 1.87 (1.41–2.48) |
| A375 | Melanoma | 0.39 (0.31–0.48) |
| SKMEL28 | Melanoma | 1.31 (1.04–1.65) |
| RCC7 | Renal cell carcinoma | 0.94 (0.74–1.19) |
| A-549 | Lung adenocarcinoma | 1.17 (0.95–1.45) |
| H1993 | Lung adenocarcinoma | 2.14 (1.89–2.43) |
| IMR32 | Neuroblastoma | 0.24 (0.10–0.54) |
| HTB-14 | Glioma | 1.56 (1.08–2.26) |
| Non-cancer cell | Cell type | IC50 of MGL-BL929 in U/ml |
| 533b | Skin fibroblast | 4.7 |
| CDG-IIc | Skin fibroblast | >10 |
↵a SW480 and SW620 colorectal cancer cells originate respectively from the primary tumor and a metastatic site from a single individual.
↵b Primary 533 skin fibroblasts originated from a normal child.
↵c CDG-II cells were from an individual with congenital disorder of glycosylation II. Cells were counted after 72-h exposure to MGL-BL929. Dose-effect plots were obtained with the CalcuSyn v2 software.